-+ 0.00%
-+ 0.00%
-+ 0.00%

Moderna Publishes Q3 2026 Earnings Call Transcript

PUBT·11/20/2026 14:11:22
Listen to the news
Moderna Publishes Q3 2026 Earnings Call Transcript
  • Moderna's third-quarter 2026 earnings call featured CEO Stephane Bancel, CFO Jamey Mock, President Stephen Hoge, development chief David Berman and analysts.
  • Mock raised full-year revenue growth guidance to 15%-25% from up to 10%; quarterly revenue rose 29% to $1.3 billion.
  • Quarterly net income reached $162 million versus a year-earlier loss; full-year R&D expense guidance fell $200 million to $2.7 billion.
  • Intismeran reduced melanoma recurrence or death risk by 42% in Phase III; management targets a regulatory submission this year with Merck.
  • Management halted plans for another norovirus trial cohort following a failed interim early-success analysis, pending discussions with regulators.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moderna Inc. published the original content used to generate this news brief on November 20, 2026, and is solely responsible for the information contained therein.